25/06/2024
Spermosens AB Announces Revised Strategy
Spermosens announce a revised strategy emphasizing an ambitious clinical
study, commercial partnerships, and operational efficiency. Starting in Q3 2024, the company will initiate a clinical study at the Reproductive Medicine Center (RMC) in Malmö to demonstrate the diagnostic value of its unique JUNO-Checked product.
Spermosens will intensify business development globally to identify the right
commercial partners through license deals in key markets for its ground-breaking JUNO-Checked product, which has the potential to help couples struggling with infertility.
Spermosens is preparing for an upcoming clinical study conducted at RMC in Malmö with Dr. Ingela Liljeqvist Soltic as principal investigator. Based on power-analysis the study is set up to involve an estimated 250 couples with so-called unexplained infertility undergoing IVF treatment. The purpose of the study is to investigate the male fertility related to a molecular recognition between s***m cells and oocyte via binding of two important proteins. A
positive outcome from this study can enhance IVF treatments, become a valuable diagnostic tool for s***m banks and as well to help couples experiencing fertility challenges prior to IVF treatment.
Spermosens is attracting interest from several companies in the field of assisted reproductive treatments (ART) and are actively pursuing strategic partnerships through licensing deals in several attractive markets, including the US and Japan. This strategic shift enhance efficiency, reduce costs, and position Spermosens optimally for success.
Dr. Tore Duvold, CEO of Spermosens, comments: “I am genuinely excited about theopportunity to help people struggling to have their own children. Our technology stands out as it may offer a personalized and improved fertility treatment, potentially leading to better fertility rates and a simpler treatment process. After thoroughly analysing our technology, strategic options, organization, and R&D partners, it is clear that we must now focus all our efforts on demonstrating the diagnostic value of our product and
seeking the right commercial partners to successfully bring it to the market. This requires us at Spermosens to be both efficient and cost-conscious. A positive outcome from the clinical study will be immensely valuable to both patients and our shareholders.”
Full story: https://lnkd.in/dBzhv8pk
The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name S***M. For more information, see www.s***mosens.com
hashtag hashtag hashtag hashtag hashtag hashtag hashtag
